Fred Aslan is CEO at Artiva Biotherapeutics, Inc. (ARTV). They have made 3 open-market trades across 1 company since 2025, most recently 2026-10-06.
CIK 0001909362
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ARTV | 1,519,606 | $8.9M |
Shares reported on the most recent Form 4, priced at the 2026-10-07 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ARTV | SELL · 10b5-1 | 2026-10-06 | 2026-10-07 | $7.20 | $169K | — | — | — |
| ARTV | SELL | 2026-10-05 | 2026-10-06 | $6.84 | $422K | -17.0% | — | — |
| ARTV | SELL · 10b5-1 | 2026-09-08 | 2026-09-09 | $10.92 | $256K | -26.1% | -34.5% | — |
| ARTV | SELL | 2026-09-03 | 2026-09-04 | $11.16 | $690K | -22.2% | -34.1% | — |
| ARTV | SELL | 2026-05-19 | 2026-05-19 | $9.01 | $244K | -14.7% | +11.5% | +33.7% |
| ARTV | SELL · 10b5-1 | 2025-12-15 | 2025-12-15 | $6.00 | $19K | -32.3% | -22.5% | -0.4% |
| ARTV | SELL · 10b5-1 | 2025-11-17 | 2025-11-17 | $3.38 | $22K | +4.2% | +19.7% | +13.9% |
| ARTV | SELL · 10b5-1 | 2025-10-17 | 2025-10-17 | $6.00 | $153K | -22.4% | -38.0% | -21.2% |
| ARTV | SELL · 10b5-1 | 2025-08-15 | 2025-08-18 | $2.73 | $70K | +1.9% | -26.5% | +13.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.